

Brief description of the project

” INOVA a+ RESEARCH-DEVELOPMENT CENTER AND CRITICAL MEDICINES PRODUCTION SITE”

I. Project title: ” INOVA a+ RESEARCH-DEVELOPMENT CENTER AND CRITICAL MEDICINES PRODUCTION SITE”

II. Applicant: ANTIBIOTICE S.A.

III. Funding program:

- **Funder:** Managing Authority for the Health Programme (AMPS) under the Ministry of Investments and European Projects (MIPE)
- **Programme:** Health Programme, Priority 9, Action A
- **Call for projects:**”Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the AMPS”
- **Deadline** for project submission: August 29, 2025.

IV. Specific field of STEP: The project proposed by Antibiotice S.A. falls within: Biotechnologies and Critical Medicines.

V. Estimated project budget

Estimated values	Euro	Lei <i>1 euro = 4.9758 lei as per the Applicant's Guide</i>
Total value of the project (eligible + non-eligible costs), excluding VAT	75,742,174.70	376,877,912.87

Within the project, several types of state aid and de minimis aid are granted, depending on the category of expenditure, in accordance with the state aid scheme approved by the *Order of the Minister of Investments and European Projects no. 330/21.02.2025*, and, respectively, as per the de minimis aid scheme approved by the *Order of the Minister of Investments and European Projects no. 329/21.02.2025*.

VI. Estimated project duration: 48 months (January 2026 – December 2029).

VII. Project location: City of Iasi, 1 Valea Lupului St., Antibiotice SA manufacturing site.

VIII. Overall objective of the project: making an investment in research- development and production facilities in Antibiotice S.A., contributes to the objectives of the Strategic Technologies for Europe Platform (STEP), according to the art. 2 of the Regulation (EU) 2024/795:

(a) supporting the development or production of critical technologies across the European Union or protecting and strengthening the corresponding value chains;

(b) overcoming shortages of labour and essential skills for all types of quality jobs, in support of achieving the first objective mentioned, according to the "Communication of the Commission of 8.5.2024 C(2024) 3148 - Guidance note on certain provisions of Regulation (EU) 2024/795 establishing the Strategic Technologies for Europe Platform (STEP)."

IX. Project activities:

- Activities that take place before project submission;
- Activities that will take place after project submission;
- Activities that will take place after the signing of the financing contract.

X. Project technical data

Investment design documentation:

The project is currently in the design phase titled "Feasibility Study", as regulated by Government Decision no. 907/2016 on the stages of development and the standard content of technical and economic documentation for investment objectives/projects financed from public funds.

Inova a+ Research & Development Center: technical specifications

Dimensions of *Inova a+*:

- Built-up area: 2,462.3 mp
- functional area proposed for the *Inova a+* ground floor;
- functional area proposed for the *Inova a+* first floor;
- functional area proposed for the *Inova a+* second floor.

Critical medicines manufacturing site: technical specifications

- Built-up area: 1,701.6 mp

XI. Research-development activity at the Inova a+ Center: a brief description

The investment in the new Inova a+ Research-Development Center represents a strategic step for Antibiotice, aligned both with the internal growth and innovation objectives and with the above-mentioned priorities of the STEP program (Strategic Technologies for Europe Platform) established by the European Union.

The STEP program aims to accelerate the development and adoption of strategic technologies in the EU, with a focus on health, green technologies, biotechnologies, and digitalization.

XII. Portfolio of products under the project - The product portfolio within the project includes critical medicines from various therapeutic classes.

Explanatory material for items 1, 2, and 3 on the Agenda of the Ordinary General Meeting of Shareholders, dated 26.08.2025

Considering the following:

1. The intention of Antibiotice S.A. to initiate the project *"Inova a+ Research-Development Center and Critical Medicines Production Site"*, a process requiring substantial investments over the medium and long term;
2. The company's initiative to submit this project for funding under the Health Programme, Call for projects *"Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector"* organized by Managing Authority for the Health Programme (AMPS), Priority 9 *"Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector"*;
3. The requirements set out in the Applicant's Guide for the project call *"Support for STEP-compatible projects submitted under the call for project ideas in the field of health / with applicability in the health sector, launched by AMPS"* - Annex to the Order of the Minister of Investments and European Projects no. 400/27.02.2025, (especially the requirements included in the chapter 5.1.1.1.2. *Financial capacity of the applicant/partners* from the Applicant's Guide and the Criterion no. 6 from the Annex no. 6 - Eligibility Checklist);
4. Given that the project is currently in the feasibility study preparation phase, in accordance with the Government Decision no. 907/2016 regarding the preparation stages and the standard content of the technical-economic documentation for investment objectives/projects financed from public funds, it is not currently possible to precisely determine the related expenditure and technical-economic indicators";
5. The provisions of art. 111, para. (2) of Company Law no. 31/1990, which establish the authority of the Ordinary General Meeting of Shareholders to decide on any matter included on the agenda.

The Management Board of Antibiotice SA, meeting in the session of 24.07.2025, decided to convene the Ordinary General Meeting of Shareholders on 26/27.08.2025, with the following items on the agenda:

1. *Approval of the project entitled " Inova a+ Research-Development Center and Critical Medicines Production Site" which will be submitted for funding under the Health Program, Project Call "Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program Managing Authority (AMPS)", Priority 9, "Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector" and the related expenses in value of 376,877,912.87 lei, excluding VAT.*

Antibiotice S.A. undertakes to ensure that it has the financial capacity to provide its own contribution to both the eligible and non-eligible project expenditures, under the conditions of subsequent reimbursement/settlement of the expenses. Antibiotice S.A. undertakes, for a 5-year period from the date of completion of the investment, in accordance with the state aid scheme and the provisions of Article 65 of Regulation (EU) No. 2021/1060, to maintain the investment made by covering the related operating and maintenance costs, as well as the necessary associated services, in order to ensure its financial sustainability.

2. *Approval of the technical and economic indicators of the project entitled “ Inova a+ Research-Development Center and Critical Medicines Production Site”, which will be submitted for funding under the Health Program, Project Call “Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, conducted by Health Program Managing Authority” , Priority 9, “Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector”.*
3. *Authorization of the Management Board to issue resolutions approving, based on supporting documentation, the exact amount of expenses related to the project “ Inova a+ Research-Development Center and Critical Medicines Production Site” and its technical-economic indicators which will be submitted for funding under the Health Program, Project Call “Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program Managing Authority (AMPS)” , Priority 9, Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector, provided they are kept within the maximum value of 376,877,912.87 lei, excluding VAT.*

Antibiotice SA

Legal and Corporate Governance Director,
Liviu VATAVU, Legal Adviser